Cargando…
First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288417/ http://dx.doi.org/10.1186/2051-1426-2-S3-P12 |
| _version_ | 1782351968431243264 |
|---|---|
| author | Evans, Manon Guest, Ryan Rothwell, Dominic Burt, Debbie Kirillova, Natalia Haughton, Jennifer Chow, Shien Thistlethwaite, Fiona Gilham, David Hawkins, Robert |
| author_facet | Evans, Manon Guest, Ryan Rothwell, Dominic Burt, Debbie Kirillova, Natalia Haughton, Jennifer Chow, Shien Thistlethwaite, Fiona Gilham, David Hawkins, Robert |
| author_sort | Evans, Manon |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288417 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42884172015-01-15 First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial Evans, Manon Guest, Ryan Rothwell, Dominic Burt, Debbie Kirillova, Natalia Haughton, Jennifer Chow, Shien Thistlethwaite, Fiona Gilham, David Hawkins, Robert J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288417/ http://dx.doi.org/10.1186/2051-1426-2-S3-P12 Text en Copyright © 2014 Evans et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Evans, Manon Guest, Ryan Rothwell, Dominic Burt, Debbie Kirillova, Natalia Haughton, Jennifer Chow, Shien Thistlethwaite, Fiona Gilham, David Hawkins, Robert First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial |
| title | First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial |
| title_full | First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial |
| title_fullStr | First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial |
| title_full_unstemmed | First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial |
| title_short | First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial |
| title_sort | first generation anti-cd19 chimeric antigen receptor-modified t cells for management of b cell malignances: initial analysis of an ongoing phase i clinical trial |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288417/ http://dx.doi.org/10.1186/2051-1426-2-S3-P12 |
| work_keys_str_mv | AT evansmanon firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT guestryan firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT rothwelldominic firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT burtdebbie firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT kirillovanatalia firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT haughtonjennifer firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT chowshien firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT thistlethwaitefiona firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT gilhamdavid firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial AT hawkinsrobert firstgenerationanticd19chimericantigenreceptormodifiedtcellsformanagementofbcellmalignancesinitialanalysisofanongoingphaseiclinicaltrial |